Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 15/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 15/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 15/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 14/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 13/20 | 0.55 |
| ▸ | CCR5 | P51681 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14413637 | 1.00 | CHRM4 (0.55) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL2274955 | 1.00 | CHRM4 (0.55) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL2280188 | 0.92 | CHRM4 (0.48) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL2275630 | 0.91 | CHRM4 (0.46) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL2275625 | 0.91 | CHRM4 (0.46) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL2273660 | 0.89 | CHRM2 (0.42) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL2273666 | 0.89 | CHRM2 (0.42) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL3020781 | 0.88 | CHRM4 (0.52) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL3021197 | 0.88 | CHRM4 (0.52) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL2275206 | 0.87 | CHRM4 (0.44) | CHRM4CHRM5CHRM1CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996189-B1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2012-09-26 | — | — | EP | disclosed |
| US-20110207777-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | TELECOM IP LIMITED | 2011-08-25 | — | — | US | disclosed |
| EP-1996189-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007107567-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207777-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | CHRM4 3/4885CHRM5 4/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.